Abstract BACKGROUND Adjunctive host-directed therapies are investigated that modulate host immune responses to reduce excessive inflammation and prevent tissue damage in tuberculosis (TB). Macrolides, including azithromycin, were shown to possess anti-inflammatory and immune-modulatory effects in addition to their antibacterial effects. In the current trial, we investigated whether azithromycin enhances resolution of systemic and pulmonary inflammation […]
Azithromycin as host-directed therapy for pulmonary tuberculosis – a randomized pilot trial.
February 11, 2025
J Infect Dis